ERBB2 and breast carcinoma: PTEN modulated trastuzumab sensitivity in HER2-overexpressing breast cancer, because of its opposition to phosphoinositide 3-kinase (PI3K) downstream signaling.12 Based on the correlation of high Fib status and trastuzumab treatment failure as shown above, we further evaluated the relationship between Fib status and PTEN.